|
|
Category:
Press
» Health & Fitness |
|
Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim (Popularity:  )
Arpida Ltd (SWX: ARPN) announced today the results of a Phase I trial investigating the possible interaction between intravenous iclaprim and warfarin. Warfarin is widely used for the prophylaxis of thrombosis and embolism and its dosing needs to be well-controlled.The drug-drug interaction study comprised 24 healthy volunteers and was performed in Germany. Dosing of warfarin with and without pre- and co-administration of iclaprim (1.6 mg/kg infused over 60 minutes) was ...
|
BioMS Medical to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference (Popularity: )
http://www.biomsmedical.com
BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference in New York. WHEN: Monday, November 5th at 3:20 pm (Local Time) WHERE: New York Palace Hotel, New York About Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference ----------------------------------------------------------------------- The Conference will ...
|
Kiadis Pharma Announces ATIR Interim Clinical Results (Popularity: )
http://www.kiadis.com
Kiadis Pharma today announced interim results of a physician initiated European Phase II clinical study for its lead product ATIR. Professor Velardi from the University of Perugia in Italy presented the successful treatment of thirteen end stage blood cancer patients with a mismatched bone marrow transplantation during the 5th workshop on "Haploidentical Stem cell Transplantation" in Catania, Italy. The results are an important milestone in the development of ATIR as ...
|
Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund (Popularity: )
http://www.gildehealthcare.nl
Gilde Healthcare Partners, a rapidly growing European venture capital firm, today announced the closing of its EUR 150 million (USD 213 million) venture fund, Gilde Healthcare II (GHC II). The new fund, which is Gilde's second healthcare fund, is one of the largest venture funds raised to invest in European healthcare opportunities. GHC II was backed by current investors in Gilde Healthcare Funds, who have been joined by a small ...
|
Pelosi: Tonight's Strong Bipartisan Vote for Children's Health Insurance a Victory for America's Children (Popularity: )
Speaker Nancy Pelosi spoke on the House floor tonight to support the Children Health Insurance Program bill, which passed by a bipartisan vote of 265 to 159. Below are her remarks as prepared: "Tonight is a bipartisan victory for America's children and families. "10 million. That is how many reasons there are to support this bipartisan CHIP legislation. 10 million American children will receive CHIP health coverage under this bill ...
|
Senate Passes 'Mental Health Parity' (Popularity: )
http://www.nmha.org
Mental Health America commends the United States Senate for passing critical legislation today to end mental health insurance discrimination, and its sponsors, Senators Pete Domenici (R-N.M.), Michael B. Enzi (R-Wyo.) and Edward Kennedy (D-Mass.) for their leadership. The bill -- S. 558, the Mental Health Parity Act of 2007 -- will ensure that Americans with employer-sponsored health insurance and their families receive mental health care coverage at the same level ...
|
Introducing a New Clinical Relationship Management Solution from the Makers of the Clinical Conductor Clinical Trial Management System (Popularity: )
http://www.bio-optronics.com
The number of organizations it takes to complete a clinical trial is overwhelming: from investigative sites, sponsors and institutional review boards to site management organizations, clinical relationship management is often a taxing pursuit for clinical trial professionals. Clinical Conductor Network Manager from Bio-Optronics aims to change this by making clinical relationship management manageable again. Clinical Conductor Network Manager, with editions for Sites and Alliances (TMOs, SMOs and Research Alliances), is ...
|
Pharmacyclics Announces Encouraging Phase 2 Data With Xcytrin(R) in Recurrent Non-Small Cell Lung Cancer Patients (Popularity: )
http://www.pharmacyclics.com
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from three open-label, multi-center Phase 2 clinical trials evaluating Xcytrin(R) (motexafin gadolinium) Injection, the company's lead product candidate, as a single-agent and in combination with chemotherapy as a second-line treatment for patients with non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen. The results were presented today at the 12th World Conference on Lung Cancer of the International Association ...
|
Flash Technology Prevents Pain From Carpal Tunnel Syndrome (Popularity: )
http://www.desk-trainer.com
The most common RSI complaint among computer users is Carpal Tunnel Syndrome, or wrist pain, arm pain and stiff fingers. Many of the existing approaches to treatment and prevention of this problem have less than satisfactory results for many people. To help fight this prevalent problem, CarpalTunnelInformation.com has extensive information about the causes, symptoms and treatments of Carpal Tunnel Syndrome. It also offers a series of free exercises which can ...
|
Authentidate Launches Inscrybe Office to Bring Trusted Document Exchange to a New Level for Enterprises and the Mass Market (Popularity: )
http://www.authentidate.com
Authentidate Holding Corp. (Nasdaq: ADAT) today announced the launch of Inscrybe(TM) Office, which provides the most advanced suite of features supporting the auditable online exchange of documents simply using a web browser. Inscrybe Office is based on Authentidate's proven Inscrybe suite of capabilities serving the document exchange needs of large enterprises today. The new web-based service combines powerful features, such as electronic signatures, content authentication and trusted time stamps using ...
|
|
|
